# Acadia Pharmaceuticals Inc: overview

ACAD · Nasdaq · CIK 1070494 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/acad.md) · [Financials](/companies/acad/financials.md) · [Filings](/companies/acad/filings.md) · [Insiders](/companies/acad/insiders.md)

Latest reported revenue: [$308.0m](/filings/0001193125-26-333243.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-333243).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [250](/filings/0001193125-25-267453.md) | [260 d](/filings/0001193125-26-072519.md) | [244](/filings/0001193125-26-209731.md) | [265](/filings/0001193125-26-333243.md) | [279](/filings/0001193125-25-267453.md) | [284 d](/filings/0001193125-26-072519.md) | [268](/filings/0001193125-26-209731.md) | [308](/filings/0001193125-26-333243.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [12.6%](/filings/0001193125-25-267453.md) | [59.1% d](/filings/0001193125-26-072519.md) | [7.9%](/filings/0001193125-26-209731.md) | [12.2%](/filings/0001193125-26-333243.md) | [12.8%](/filings/0001193125-25-267453.md) | [6.1% d](/filings/0001193125-26-072519.md) | [(1.7%)](/filings/0001193125-26-209731.md) | [12.3%](/filings/0001193125-26-333243.md) |
| Net margin | % | [13.1%](/filings/0001193125-25-267453.md) | [55.4% d](/filings/0001193125-26-072519.md) | [7.8%](/filings/0001193125-26-209731.md) | [10.1%](/filings/0001193125-26-333243.md) | [25.8%](/filings/0001193125-25-267453.md) | [96.3% d](/filings/0001193125-26-072519.md) | [1.4%](/filings/0001193125-26-209731.md) | [10.2%](/filings/0001193125-26-333243.md) |
| Diluted EPS | $ per share | [0.20](/filings/0001193125-25-267453.md) | not reported | [0.11](/filings/0001193125-26-209731.md) | [0.16](/filings/0001193125-26-333243.md) | [0.42](/filings/0001193125-25-267453.md) | not reported | [0.02](/filings/0001193125-26-209731.md) | [0.18](/filings/0001193125-26-333243.md) |
| Free cash flow | $m | [63.2 d](/filings/0001193125-25-267453.md) | [39.9 d](/filings/0001193125-26-072519.md) | [20.3](/filings/0001193125-26-209731.md) | [63.7 d](/filings/0001193125-26-333243.md) | [73.9 d](/filings/0001193125-25-267453.md) | [(52.7) d](/filings/0001193125-26-072519.md) | [28.8](/filings/0001193125-26-209731.md) | [95.7 d](/filings/0001193125-26-333243.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [484](/filings/0000950170-24-021473.md) | [517](/filings/0000950170-25-029253.md) | [726](/filings/0001193125-26-072519.md) | [958](/filings/0001193125-26-072519.md) | [1,072](/filings/0001193125-26-072519.md) |
| Gross margin | % | [97.8%](/filings/0000950170-23-004757.md) | [98.0%](/filings/0000950170-24-021473.md) | [94.3%](/filings/0000950170-24-021473.md) | not reported | not reported |
| Operating margin | % | [(35.2%)](/filings/0000950170-24-021473.md) | [(43.2%)](/filings/0000950170-25-029253.md) | [(10.1%)](/filings/0001193125-26-072519.md) | [24.1%](/filings/0001193125-26-072519.md) | [9.8%](/filings/0001193125-26-072519.md) |
| Net margin | % | [(34.7%)](/filings/0000950170-24-021473.md) | [(41.8%)](/filings/0000950170-25-029253.md) | [(8.4%)](/filings/0001193125-26-072519.md) | [23.6%](/filings/0001193125-26-072519.md) | [36.5%](/filings/0001193125-26-072519.md) |
| Diluted EPS | $ per share | [(1.05)](/filings/0000950170-24-021473.md) | [(1.34)](/filings/0000950170-25-029253.md) | [(0.37)](/filings/0001193125-26-072519.md) | [1.36](/filings/0001193125-26-072519.md) | [2.30](/filings/0001193125-26-072519.md) |
| Free cash flow | $m | [(127)](/filings/0000950170-24-021473.md) | [(114)](/filings/0000950170-25-029253.md) | [16.7](/filings/0001193125-26-072519.md) | [157](/filings/0001193125-26-072519.md) | [105](/filings/0001193125-26-072519.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/acad/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $1.09bn | 42,912,904 |  | Added +16,214 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $569.6m | 22,515,173 |  | Added +964,252 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $229.6m | 9,076,212 |  | Added +743,441 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $223.6m | 8,838,450 |  | Added +166,805 |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $180.8m | 7,144,524 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $145.8m | 5,763,750 |  | Added +102,350 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $93.5m | 3,694,988 |  | Added +539,828 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $85.0m | 3,358,129 |  | Reduced −106,560 |
| [Palo Alto Investors LP](/funds/1306923.md) | 2026-06-30 | $72.5m | 2,864,096 |  | Reduced −8,599 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $65.3m | 2,580,115 |  | Added +1,022,311 |

## Recent filings

[All 1,087 filings](/companies/acad/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-23 | 16:51 ET | [8-K](/filings/0001193125-26-430596.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-430596 |
| 2026-09-24 | 17:11 ET | [8-K](/filings/0001193125-26-401157.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-401157 |
| 2026-09-11 | 17:15 ET | [8-K](/filings/0001193125-26-389400.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-389400 |
| 2026-08-05 | 18:12 ET | [10-Q](/filings/0001193125-26-333243.md) | Quarterly report, period 2026-06-30 | 0001193125-26-333243 |
| 2026-08-04 | 16:16 ET | [8-K](/filings/0001193125-26-332858.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-332858 |
| 2026-05-29 | 16:05 ET | [8-K](/filings/0001193125-26-248242.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-248242 |
| 2026-05-07 | 19:50 ET | [10-Q](/filings/0001193125-26-209731.md) | Quarterly report, period 2026-03-31 | 0001193125-26-209731 |
| 2026-05-06 | 16:50 ET | [8-K](/filings/0001193125-26-209253.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-209253 |
| 2026-05-01 | 17:34 ET | [8-K](/filings/0001193125-26-197957.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-197957 |
| 2026-04-24 | 18:05 ET | [DEF 14A](/filings/0001193125-26-174163.md) | Proxy statement, period 2026-05-29 | 0001193125-26-174163 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-072519.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/35e90215-3ce3-4a53-b93d-83c89692047d)

## About the filer

- CIK: 1070494
- Tickers: ACAD
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 20:22 ET. No prices; not investment advice.